Psyched Wellness Commences Pre-clinical Trials or Amanita Muscaria
December 28, 2020
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Lobe Sciences Announces Upsizing and First Closing of Non-brokered Private Placement
December 28, 2020
Ryan Allway December 28th, 2020 Psychedelics Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“), is pleased to announce that it has upsized its previously announced non-brokered private placement of units (the “Units“) from $2,000,000 to up to $2,700,000 (the “Offering“) and has completed a first... Read more
Mindset Pharma to Commence Trading on the CSE on December 23, 2020 Under the Symbol “MSET”
December 23, 2020
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
MagicMed zielt mit dem Programm für pharmazeutische Derivate auf einen massiven Markt ab
December 23, 2020
Ryan Allway December 23rd, 2020 Exclusive, German, Psychedelics Der Markt für Psychedelika ist aufgrund des unentdeckten therapeutischen Potenzials psychedelischer Moleküle schwer zu berechnen. Die wissenschaftliche Gemeinschaft hat gezeigt, dass Psychedelika mehrere Milliarden-Dollar-Märkte im Bereich Gehirn und psychische Gesundheit behandeln können. MagicMed Industries zielt darauf ab, Teile beider Märkte zu... Read more
MagicMed Targets Massive Market with Pharmaceutical Derivatives Program
December 23, 2020
Ryan Allway December 23rd, 2020 App, Exclusive, Psychedelics, Top Story The psychedelics market is hard to calculate because of the undiscovered therapeutic potential of psychedelic molecules. The scientific community has shown that psychedelics could treat multiple multibillion-dollar markets in the brain and mental health space. MagicMed Industries positions itself... Read more
Ryan Allway December 22nd, 2020 Psychedelics NEW WAVE HOLDINGS CORP. (the “Company” or “New Wave“) (CSE: SPOR) (FWB: 0XM2) (OTC: TRMNF) an investment issuer that provides capital and support services, is pleased to announced that further to its press release dated December 15, 2020, it has entered into a... Read more
Havn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an Authorized Products Listing
December 22, 2020
Ryan Allway December 22nd, 2020 Psychedelics Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the “Company” or “Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds, the development of a full range of natural healthcare products, and innovative mental health treatment, is pleased to announce a product listing agreement for... Read more
Novamind Receives CSE Conditional Listing Approval Under the Ticker “NM”
December 22, 2020
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any... Read more
Psychedelics Production Challenges & Solutions
December 21, 2020
Ryan Allway December 21st, 2020 App, Exclusive, Psychedelics, Top News Psilocybin and other tryptamine-based compounds could become blockbuster therapeutics for the treatment of depression, post-traumatic stress disorder and other difficult to treat psychiatric conditions. While many clinical trials are underway, researchers are turning their attention toward the problem of... Read more
Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials
December 21, 2020
Ryan Allway December 21st, 2020 Psychedelics, Top News DENVER, Dec. 21, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that... Read more
